Gary Clark: Unfiltered

As Mile High Flea Market turns 50, it's more than a community party. It's a powerful case study in economic resilience and a blueprint for retail's future.

Sparklight Business is launching a unified communications platform, but can it challenge giants like Microsoft and Zoom in a crowded market? A look at the strategy.

Activist investor Oasis Management, holding 19.5% of Kakaku.com, rejects a board-backed buyout offer, demanding a higher price and igniting a fierce debate.

The era of AI experimentation is over. As Reuters Events convenes a high-stakes summit in Austin, the C-suite faces a new mandate: prove the ROI.

Needham Bank opens a new branch in the high-stakes Prudential Center, betting that decades of leadership experience and genuine community investment can win in Boston.

The Army just handed M1 a $10B, 26-year deal to train its pilots. This isn't just a contract; it's a radical bet on private industry and AI to redefine the aviator.

From AI security to quantum navigation, VetsinTech's latest finalists reveal a powerful trend: veteran founders are building tomorrow's critical infrastructure.

On the 14th anniversary of his abduction in Syria, the call to free Austin Tice grows louder, yet the journalist and veteran remains missing.

PMV Pharma's rezatapopt shows remarkable results for a tough cancer by reactivating a key defense. A deep dive into the science, finances, and patient hope.

TestMu AI's massive virtual conference isn't just about code. It's a strategic play to own the critical, high-stakes market of validating what AI builds.

Bonerge is betting that cellular recovery is the key to mitigating the high cost of night shift work. Its real-world trial could redefine human capital investment.

With federal loans for med students cut, AACOM's new Sallie Mae deal fills a vital gap. But does this private-sector solution come at too high a price?

The footwear giant just launched a mascot, but this isn't child's play. It's a calculated pivot from fleeting collabs to building a scalable, long-term asset.

Revenue is down, but Bragg Gaming's margins are up. A new chairman, a major acquisition, and deep cuts signal a high-stakes bet on a leaner future.

Rigel's VEPPANU is the first FDA-approved PROTAC, a new class of drug that destroys disease proteins. This is the story behind the science and the numbers.

Record shareholder returns and massive cash flow paint a rosy picture, but a deeper look at Pan American's Q2 results reveals operational stumbles.

With promising data for its GX-03 cream in an underserved patient group, Turn Therapeutics expands its trial, hires an ex-FDA head, and eyes a new disease.

A legacy battery gets a high-tech upgrade. AGY and Terra Supreme are using advanced glass fibers to give lead-acid a new lease on life, challenging lithium.

Last Mile Health's Hilton Prize isn't charity. It's a strategic investment in a sustainable, localized economic model that de-risks healthcare delivery.

A posthumous memoir from a NASA pioneer reveals how frontier ingenuity built a strategic asset in Alaska, a story more relevant than ever in 2026.